Fig. 1 Prophylactic, neutralization, and therapeutic efficacy of HPAC.

Slides:

Advertisements

Similar presentations

Targeting Herpes Simplex Virus-1 gD by a DNA Aptamer Can Be an Effective New Strategy to Curb Viral Infection Tejabhiram Yadavalli, Alex Agelidis, Dinesh.

Advertisements

Targeting Herpes Simplex Virus-1 gD by a DNA Aptamer Can Be an Effective New Strategy to Curb Viral Infection Tejabhiram Yadavalli, Alex Agelidis, Dinesh.

Fig. 1 BX795 suppresses HSV-1 infection.

Fig. 4 Altitudinal distributions of ice thickness change (m year−1) for the 650 glaciers. Altitudinal distributions of ice thickness change (m year−1)

Fig. 3 Cytosolic delivery of fluorescent proteins.

Fig. 2 Boronic acid–rich dendrimer in cytosolic delivery.

Fig. 2 Global production, use, and fate of polymer resins, synthetic fibers, and additives (1950 to 2015; in million metric tons). Global production, use,

Vibrational spectra of medieval human bones (Leopoli-Cencelle, Italy)

Fig. 4 Rotation of nuclei in oocytes in the primordial follicles.

Fig. 1 Examples of experimental stimuli and behavioral performance.

Fig. 2 Some examples of weekly forecasts (the number of the forecasts are reported on Table 1). Some examples of weekly forecasts (the number of the forecasts.

Fig. 4 Resynthesized complex boronic acid derivatives based on different scaffolds on a millimole scale and corresponding yields. Resynthesized complex.

HT synthesis of boronic acids using the building block approach

Fig. 6 Comparison of properties of water models.

Single-base validation using ligation-amplification method and qPCR

Fig. 2 Ferroelectric domains resolved in WTe2 single crystals.

Fig. 2 The glucose binding and charge-switch study.

Fig. 3 Glucose- and structure-dependent insulin release.

Fig. 3 Scan rate effects on the layer edge current.

Fig. 1 Synthesis and testing of nIRCats.

Fig. 1 Product lifetime distributions for the eight industrial use sectors plotted as log-normal probability distribution functions (PDF). Product lifetime.

Fig. 1 Distribution of total and fake news shares.

Fig. 1 Genes up-regulated in Zic5 KO cells correlate with the increased glycolytic state. Genes up-regulated in Zic5 KO cells correlate with the increased.

Fig. 2 NAD+-sensitized reduction of O2and oxidation of H2O.

Fig. 2 2D QWs of different propagation lengths.

Fig. 2 ODN enhances EV transfer between cells expressing TLR9.

Electronic structure of the oligomer (n = 8) at the UB3LYP/6-31G

Fig. 2 EUV TG signal. EUV TG signal. Black lines in (A), (B), and (C) are the EUV TG signals from Si3N4 membranes at LTG = 110, 85, and 28 nm, respectively,

Fig. 6 WPS imaging of different chemical components in living cells.

Fig. 4 Activation of mitochondrial apoptosis pathway by n-HA.

Fig. 1 NDR2 facilitates RNA virus–induced IFN-β, IL-6, and TNF-α production via a kinase activity–independent mechanism in macrophages. NDR2 facilitates.

Fig. 1 Histograms of the number of first messages received by men and women in each of our four cities. Histograms of the number of first messages received.

Fig. 1 Synthesis and characterization of Dox-CBD-SA.

Fig. 4 The mechanical performances of thermally stable click-ionogels.

Fig. 4 Evolution of fraction of sickled RBCs under hypoxia.

Fig. 3 Production of protein and Fe(II) at the end of growth correlated with increasing concentrations of ferrihydrite in the media that contained 0.2.

Fig. 6 Global sensitivity analysis illustrates the key model parameters that determine the sickling of RBCs. Global sensitivity analysis illustrates the.

Fig. 3 Prophylactic or therapeutic use of DECON protects from herpes infections in vitro. Prophylactic or therapeutic use of DECON protects from herpes.

Fig. 4 Alternate-day ocular dosing with DECON curbs HSV-1 in a murine model of ocular infection. Alternate-day ocular dosing with DECON curbs HSV-1 in.

Release of phototethered siRNA from the hydrogels and RNA bioactivity

Fig. 2 Viperin promotes methionine oxidation of KSHV helicase.

Fig. 5 Predictions of the efficacy of sickling inhibitors with the kinetic model. Predictions of the efficacy of sickling inhibitors with the kinetic model.

Fig. 5 Comparison of the liquid products generated from photocatalytic CO2 reduction reactions (CO2RR) and CO reduction reactions (CORR) on two catalysts.

Fig. 1 Location of the Jirzankal Cemetery.

Fig. 4 CO2 emission changes triggered by the JJJ clean air policy.

Fig. 6 MSC encapsulation in vitro within PdBT cross-linked gels.

Fig. 2 Nanofibers inhibit CA IX–associated cancer cell behaviors.

Multiplexed four- and eight-channel devices for rapid processing

Fig. 6 The combined therapeutic efficacy of N-pepABS and low dose of Dox on MDA-MB-231 xenografts. The combined therapeutic efficacy of N-pepABS and low.

Fig. 2 RVFV causes pathology within the liver, uterus, and placenta of pregnant dams. RVFV causes pathology within the liver, uterus, and placenta of pregnant.

Fig. 3 Effects of ASO and eGLP1-ASO conjugates on gene expression and protein levels in vitro in cell lines and primary mouse islet cells. Effects of ASO.

Fig. 3 Comparisons of NDVI trends over the globally vegetated areas from 1982 to Comparisons of NDVI trends over the globally vegetated areas from.

Fig. 2 BX795 is nontoxic to HCE cells at therapeutic concentration.

Fig. 4 Single-particle contact angle measurements.

ATP analogs have little effect on the conformation of the 2CARD domain

Fig. 5 Topical vaginal application of DECON on alternate days is as effective as daily systemic ACV dosing. Topical vaginal application of DECON on alternate.

Fig. 4 Cytosolic delivery of native enzymes.

Fig. 3 Supraballs and films assembled from binary 219/217nm SPs/SMPs.

Fig. 2 Supraballs and films from binary SPs.

Fig. 4 Model drug (methylene blue) release from modified and unmodified nanogels. Model drug (methylene blue) release from modified and unmodified nanogels.

Fig. 1 Schematic structure of a fluorescently labeled eGLP1-conjugated MALAT1 ASO and internalization of fluorescent eGLP1 and eGLP1-MALAT1-ASO. Schematic.

Fig. 5 The complex of antibody and dye can afford to target imaging in the NIR-II window. The complex of antibody and dye can afford to target imaging.

Fig. 3 High-tide flood extent at water levels of 1. 73, 2. 03, 2

Fig. 4 Behavior of resistance peak near density nm = 5.

Fig. 2 Comparison between the different reflective metasurface proposals when θi = 0° and θr = 70°. Comparison between the different reflective metasurface.

Fig. 4 Light-induced TRPV1 activation promotes in vitro tubulogenesis in ECFC cultures. Light-induced TRPV1 activation promotes in vitro tubulogenesis.

Fig. 5 Cytosolic delivery of toxic proteins.

Fig. 6 Methionine oxidation catalyzed by viperin increases the stability and function of RNA helicase RIG-I. Methionine oxidation catalyzed by viperin.

Fig. 4 Effects of individual picosecond and microsecond pulses.

Fig. 1 TH17 cell differentiation was severely impaired in Cxxc1-deficient mice. TH17 cell differentiation was severely impaired in Cxxc1-deficient mice.

Presentation transcript:

Fig. 1 Prophylactic, neutralization, and therapeutic efficacy of HPAC. Prophylactic, neutralization, and therapeutic efficacy of HPAC. (A) Fluorescence imaging of green fluorescent protein (GFP)–HSV-1– and GFP–HSV-2–infected human corneal epithelial cells (HCEs) or HeLa cells treated with HPAC (1 mg/ml) prophylactically. (B) GFP HSV-1 and HSV-2 viruses were neutralized with HPAC (1 mg/ml) before its application to HeLa cells, and the viral entry was measured. Blue, 4′,6-diamidino-2-phenylindole; red, phalloidin staining of actin; green, GFP virus. (C) HCEs and HeLa cells were infected with HSV-1 and HSV-2, respectively, for a period of 2 hours before the addition of mock phosphate-buffered saline (PBS) or HPAC at 1 mg/ml. Twenty-four hours after infection, fluorescence images were taken to understand the extent of viral spread in HPAC-treated samples compared to mock. Green, 17 GFP HSV-1 or HSV-2 333 GFP virus. Viral entry for prophylactic (D) and neutralization treatments (E) was quantified using a β-galactosidase reporter virus. (F) Intracellular viral load for HPAC therapeutic treatment was quantified using a plaque assay. PFU, plaque-forming units. Representative immunoblots of HSV-1 (G) or HSV-2 gB (H) protein and human glyceraldehyde-3-phosphate dehydrogenase (GAPDH) from infected HCEs or HeLa cells treated with varying concentrations of HPAC. (I) Toxicity of HPAC in vitro was evaluated by MTT [3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide] assay after the incubation of multiple concentrations of HPAC with HCEs, HeLa cells, VK2s (vaginal epithelial cells), and HFFs (human foreskin fibroblasts) for 24 hours. (J) Optical density measurements were performed by serially diluting HPAC in a 96-well plate and measuring the optical absorbance at 650 nm. Lower absorbance corresponds to a clearer solution. Data are presented as means ± SD. Significance to mock-treated cells was determined by one-way analysis of variance (ANOVA) followed by Dunnett’s multiple comparisons test (n = 3 replicates). *P < 0.05; **P < 0.01; ***P < 0.001; ****P < 0.0001. Tejabhiram Yadavalli et al. Sci Adv 2019;5:eaax0780 Copyright © 2019 The Authors, some rights reserved; exclusive licensee American Association for the Advancement of Science. No claim to original U.S. Government Works. Distributed under a Creative Commons Attribution NonCommercial License 4.0 (CC BY-NC).